Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06384911 · ClinicalTrials.gov registry record · NA
InvesT1D: Promoting Adolescent Investment in Diabetes Care
A NA study of Type 1 Diabetes, sponsored by Harvard Pilgrim Health Care.
- Recruiting
- Registry status
- NA
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT06384911: Recruiting NA study of Type 1 Diabetes, sponsored by Harvard Pilgrim Health Care.
NCT06384911 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Harvard Pilgrim Health Care. The registered enrollment target is 96 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06384911, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Harvard Pilgrim Health Care.
- RECRUITING
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management and clinical outcomes goals during the study. Researchers will compare changes in glucose levels, as well as adolescent and caregiver person-reported outcomes between groups.
Primary Outcome
Continuous glucose monitor sensor glucose measurements collected during the intervention that are in range (70-180 mg/dL)
Conditions Studied
Interventions
- BEHAVIORAL Financial Incentives Program
Study Locations (1)
Washington
- Seattle Children's - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2027-10-31 |
| Phase | NA |
What NCT06384911 shows while recruiting
NCT06384911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Financial Incentives Program is the first listed.
NCT06384911 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06384911 about?
NCT06384911 is a clinical study titled "InvesT1D: Promoting Adolescent Investment in Diabetes Care". The goal of this clinical trial is to see if a financial incentives program called InvesT1D is helpful to support diabetes management in adolescents with type 1 diabetes. Adolescent participants will be randomized to usual care or receive financial incentives for meeting diabetes self-management an...
What is the current status of trial NCT06384911?
This trial is currently recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2024-06-25. Estimated completion is 2027-10-31.
What conditions does trial NCT06384911 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT06384911?
The interventions under investigation include: Financial Incentives Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06384911?
This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06384911 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06384911's enrollment target sits among peer trials
96 59th of 198 higher than 140 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
AIDANET Pediatrics
RECRUITING · NA
-
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
RECRUITING · NA
-
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI